Han, MLK; Ignacio, RAB; Bernus, AL; Milger-Kneidinger, K; Nyaku, AN; Parker, B; Potter, V; Savic, S; Campello-Iddison, V; Cao, WH; Langmuir, P; Knorr, B.
RUXCOVID: A phase 3, randomized, placebo-controlled study evaluating the efficacy and safety of ruxolitinib in patients with COVID-19-associated cytokine storm.
CLIN CANCER RES. 2020; 26(18):
Web of Science